Treating Schizophrenia by Correcting Abnormal Brain Development
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during
the early course of schizophrenia can fundamentally correct the brain deficits associated
with the disease.
This study is funded by the National Institutes of Health.